Drug · DIN 02230694
CEREZYME
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since August 4, 2016; first marketed April 30, 1997.
- Drug Identification Number (DIN)
- 02230694
- Company (DIN owner)
- Sanofi Genzyme, A Division Of Sanofi-Aventis Canada IncToronto, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Imiglucerase A16AB02
- Class
- Human
- Record last updated
- August 5, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IMIGLUCERASE | 200 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 17, 2004: NOC 4766New Drug Submission (NDS) · Manufacturer name change
- February 12, 1997: NOC 3858New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “cerezyme”. A notice may cover another product or only some lots: read it to see what it covers.
- Archived - Cerezyme (imiglucerase for injection) - Supply and Recommendations for Restarting Cerezyme - For the PublicDecember 29, 2009 · Biologic or vaccine
- Cerezyme (imiglucerase for injection) - Supply and Recommendations for Restarting Cerezyme - For Health ProfessionalsDecember 29, 2009 · Biologic or vaccine
- Cerezyme (imiglucerase for injection), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa) and Aldurazyme (laronidase): Caution with Preparation and Administration - For Health ProfessionalsDecember 9, 2009 · Biologic or vaccine
Other DINs named CEREZYME
- DIN 02241751 · Marketed